Team Against Opioid Abuse

Welcome to TeamAgainstOpioidAbuse.com, your online resource for information about abuse-deterrent properties found in some opioid formulations. On TeamAgainstOpioidAbuse.com

Brief review of H.R. 2335

Abuse Deterrent Coalition | 05/22/15

Rates of Opioid Dispensing and Overdose After Introduction of Abuse-Deterrent Extended-Release Oxycodone and Withdrawal of Propoxyphene

JAMA Internal Medicine | 04/20/15

Opioid dispensing and prescription opioid overdoses decreased substantially after 2 major changes in the pharmaceutical market in late 2010. Pharmaceutical market interventions may have value in combatting the prescription opioid overdose epidemic, but heroin overdose rates continue to increase. Complementary strategies to identify and treat opioid abuse and addiction are urgently needed.

Abuse-Deterrent Opioids — Evaluation and Labeling

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Clinical Medical | 04/15

This guidance explains FDA’s current thinking about the studies that should be conducted to demonstrate that a given formulation has abuse-deterrent properties. The guidance makes recommendations about how those studies should be performed and evaluated and discusses how to describe those studies and their implications in product labeling.

Abuse-Deterrent Opioids: Advances in Technology (Part 1 of a 3-Part Series)

Reprinted from Pain Medicine News | Sponsored by Teva Pharmaceuticals | 04/15

Chronic pain is a serious medical condition that affects more than 100 million American adults, affecting many to the point where they are unable to work, maintain relationships, or even participate in daily tasks. It is one of the most common reasons individuals seek medical care, resulting in up to $635 billion in direct medical costs and lost productivity on an annual basis.

Prescription Drug Addicts Target Open House

Daily Real Estate News | 3/11/14

Prescription drug abusers reportedly are posing as home buyers and using open houses to raid medicine cabinets and night stands in search of drugs.

Abuse-Deterrent Opioid Formulations: Promising Technology, Unique Challenges

Institute for Patient Access | David Charles, MD and Mary Ann Chapman, PhD | 12/14

Prescription pain medications such as opioids offer important treatment options for people with severe pain, often providing relief and allowing some to resume their daily activities. Unfortunately, these drugs can be misused, abused, or diverted to others for illicit use — problems that have become pervasive across the country. Each year approximately 4.5 million Americans use prescription pain medications for nonmedical purposes, 1 contributing to more than 16,000 deaths annually.

Will Government and Payor Policies Encourage Innovation and Create Incentives for the Continued Development of Abuse Deterrent Formulations and Improvements to Existing Technologies?

BIO International Convention Presentation | J. David Haddox, DDS, MD, Vice President, Health Policy, Purdue Pharma L.P. | 6/14

Will Government and Payor Policies Encourage Innovation and Create Incentives for the Continued Development of Abuse Deterrent Formulations and Improvements to Existing Technologies?

BIO International Convention Presentation | Douglas C. Throckmorton MD Deputy Director for Regulatory Programs, CDER, FDA| 6/14

Epidemiological Confirmation of Abuse Deterrence: Measuring ADFs in the Real World is More Complicated Than We Think

CPDD June 2013 Annual Meeting Presentation | Simon H. Budman, Ph.D., Stephen Butler, Ph.D., Traci Green, Ph.D, Theresa Cassidy, MPH, Ryan Black, Ph.D. | 6/13

Opioid Prescribing Practices and Pain Management: Role of FDA

FDA Presentation | Douglas C. Throckmorton MD Deputy Director for Regulatory Programs, CDER, FDA | 10/13

FDA Perspective on Development of Abuse Deterrent Opioids

FDA Presentation | Douglas C. Throckmorton MD Deputy Director for Regulatory Programs, CDER, FDA | 10/13